Parexel and Palantir Technologies have unveiled an ambitious multi-year strategic partnership aimed at harnessing the power of artificial intelligence (AI) to elevate the delivery of clinical trials for Parexel’s clientele. This collaboration sees Parexel integrating Palantir’s Foundry and Artificial Intelligence Platform (AIP) into its clinical data platform, marking a significant leap forward in leveraging cutting-edge technology to enhance trial execution.
Elevating Clinical Trial Execution with AI
The partnership centers on enhancing Parexel’s Precision Pathway, an end-to-end operational strategy that prioritizes the utilization of clean data in clinical trials. By leveraging Palantir’s software, Precision Pathway will create an integrated digital environment to automate manual processes, enhance data discoverability, extract insights from past trials, and streamline collaboration among scientific and operational teams and their partners.
Jonathan Shough, Parexel’s Chief Information Officer, expressed excitement about the collaboration, stating, “We’re thrilled to expand our collaboration with Palantir—a leader in artificial intelligence technology—as we build on our application of AI to further improve clinical trial execution and advance our offerings in real-world evidence, advanced analytics, and health outcomes.”
Empowering Customers with Quality Data
Parexel’s customers will benefit from access to high-quality, validated data facilitated by Foundry and AIP technology. This ensures transparency throughout studies and accelerates timelines from planning to submission, ultimately enhancing efficiency and effectiveness in clinical trial processes.
Stephen Pyke, Parexel’s Chief Clinical Data and Digital Officer, emphasized the potential of AI in advancing clinical trial processes, stating, “Parexel is well positioned to rapidly scale our use of AI to enhance data quality and streamline the clinical trial process to better deliver for our customers and patients.”
Driving Strategic Insights and Accelerating Drug Development
The integration of Parexel’s end-to-end delivery model with Palantir’s AI capabilities is expected to generate strategic insights that inform drug development and expedite time to market. This collaboration underscores the commitment of both companies to drive innovation and efficiency in the pharmaceutical industry.
Lalarukh Haris Shaikh, PhD, Executive of Life Sciences at Palantir, highlighted the transformative potential of the partnership, stating, “Parexel has embraced the principles of digital transformation using generative AI at remarkable speed and scale.”
Looking Ahead: Embracing Digital Transformation
The partnership between Parexel and Palantir signifies a commitment to embracing digital transformation and leveraging AI to unlock the full potential of clinical trial processes. As the pharmaceutical landscape continues to evolve, collaborations of this nature are poised to drive significant advancements in drug development and patient care.
